nu6102 has been researched along with Benign Neoplasms in 2 studies
NU6102: structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "We generate CDKi-resistant cancer cells and find that they have reduced proliferative fitness and stably rewired cell cycle control pathways." | 1.46 | Spatial competition constrains resistance to targeted cancer therapy. ( Bacevic, K; Boszonyik, B; Fisher, D; Hochberg, ME; Krasinska, L; Noble, R; Prieto, S; Soffar, A; Vincent, C; Wael Ammar, O, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadesse, S | 1 |
| Caldon, EC | 1 |
| Tilley, W | 1 |
| Wang, S | 1 |
| Bacevic, K | 1 |
| Noble, R | 1 |
| Soffar, A | 1 |
| Wael Ammar, O | 1 |
| Boszonyik, B | 1 |
| Prieto, S | 1 |
| Vincent, C | 1 |
| Hochberg, ME | 1 |
| Krasinska, L | 1 |
| Fisher, D | 1 |
1 review available for nu6102 and Benign Neoplasms
| Article | Year |
|---|---|
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Hu | 2019 |
1 other study available for nu6102 and Benign Neoplasms
| Article | Year |
|---|---|
Spatial competition constrains resistance to targeted cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Prolifer | 2017 |